Certara (CERT) and The Competition Head-To-Head Comparison

Certara (NASDAQ:CERT) is one of 93 public companies in the “Healthcare Technology” industry, but how does it compare to its competitors? We will compare Certara to similar companies based on the strength of its earnings, valuation, analyst recommendations, institutional ownership, dividends, profitability and risk.

Volatility and Risk

Certara has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Certara’s competitors have a beta of 1.11, suggesting that their average stock price is 11% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Certara and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Certara	1	7	4	1	2.38
Certara Competitors	455	1537	2754	89	2.51

Certara presently has a consensus target price of $9.92, suggesting a potential downside of 14.29%. As a group, “Healthcare Technology” companies have a potential upside of 44.71%. Given Certara’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Certara has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Certara and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Certara	$418.84 million	-$1.60 million	-27.55
Certara Competitors	$341.86 million	-$24.15 million	12.85

Certara has higher revenue and earnings than its competitors. Certara is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

74.0% of Certara shares are owned by institutional investors. Comparatively, 42.4% of shares of all “Healthcare Technology” companies are owned by institutional investors. 1.1% of Certara shares are owned by company insiders. Comparatively, 16.2% of shares of all “Healthcare Technology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Certara and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Certara	-16.14%	3.36%	2.31%
Certara Competitors	-750.30%	-29.45%	-15.32%

Summary

Certara beats its competitors on 8 of the 13 factors compared.

Certara Company Profile

Certara provides software and consulting services that support the development and use of medicines. Its biosimulation tools help pharmaceutical and biotechnology companies model how drugs behave in the body, assess potential treatment outcomes, and inform decisions during drug research and development. The company’s offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial simulation, and drug development analysis. Certara also provides scientific and regulatory consulting, including support for regulatory submissions and strategies that use modeling and simulation to guide development programs.